Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 4/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948322 | 0.90 | ACACB (0.49) | KMT2AMEN1ACACBLTA4HADRB2 | |
| SCHEMBL951205 | 0.88 | S1PR1 (0.46) | ACACBLTA4HADRB2DRD3ADRB1 | |
| SCHEMBL948234 | 0.88 | KDM4E (0.44) | KMT2ALTA4HKDM4EMITFGAA | |
| SCHEMBL951121 | 0.87 | LTA4H (0.38) | KMT2ALTA4HKDM4EMITFGAA | |
| SCHEMBL946937 | 0.87 | KDM4E (0.42) | KMT2AMEN1CYP1A2CYP2C19KDM4E | |
| SCHEMBL948586 | 0.85 | S1PR2 (0.50) | KMT2ALTA4HCYP1A2KDM4EMITF | |
| Trifluoroacetic Acid SCHEMBL948036 | 0.83 | KMT2A (0.47) | KMT2AMEN1MAPTALOX12ACACB | |
| SCHEMBL948193 | 0.83 | S1PR2 (0.54) | KMT2ALTA4HCYP1A2KDM4EMITF | |
| SCHEMBL948875 | 0.83 | KMT2A (0.46) | KMT2ALTA4HKDM4EMITFGAA | |
| SCHEMBL950312 | 0.82 | DRD4 (0.52) | KMT2ALTA4HADRA1ADRD3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2883865-A1 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-17 | — | — | EP | disclosed |
| US-20140288034-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-09-25 | — | — | US | disclosed |
| US-8791159-B2 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20110020324-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD (JP) | 2011-01-27 | — | — | US | disclosed |
| US-7825109-B2 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| CN-1874991-A | Compounds capable of binding to the S1P receptor and pharmaceutical uses thereof | ONO PHARMACEUTICAL CO (JP) | 2006-12-06 | — | — | CN | disclosed |
| EP-1661881-A2 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288034-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | S1PR1, S1PR2, S1PR3 | KMT2A 2683/4885MEN1 458/4885MAPT 4760/4885 |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | S1PR1, S1PR3, S1PR2 | KMT2A 2637/4885MEN1 435/4885MAPT 4603/4885 |
| US-20110020324-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | S1PR1, S1PR3, S1PR2 | KMT2A 2637/4885MEN1 435/4885MAPT 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.